Subscription Plan

PIPELINE development using DrugTX.AI & Precision.AI

  • Our DrugTX.AI enables accuracy, control and higher probability of success during clinical development, manufacturing and commercialization of products.
  • Precision.AI for Novel Target and Drug Discovery. Our Precision.AI technology uses disease area focused algorithms.

DrugTX.AI for AI based clinical development, manufacturing and commercialization.

We encourage Pilot projects that cover a proof of concept for the use of the DrugTX.AI platform.

GET IN TOUCH

Clinical Development Pipeline

Tracking therapeutic progress across multiple phases

Therapeutic Area / Target / Molecule Discovery IND Phase 1 Phase 2 Phase 3

Oncology: Pancreatic Cancer, Kidney Cancer

Target: TG Alpha

Molecule: ADC/ADCGEN04

Oncology: T-cell Engager Bi-specific

Target: PD1

Molecule: AB-303: bi-specific T-Cell Engaging Antibody

CNS: NPC1, ALS, HD, PD

Target: LLM: Lipid Lysosomal Modulator

Molecule: SM/UNDC005

CNS: Alzheimer's Disease

Target: LLM: Lipid Lysosomal Modulator

Molecule: SM/UNDC005

Undisclosed - Commercial Asset

Target: Undisclosed

Molecule: SM
✓
Completed Phase
–
Pending Phase

Our collaboration partners can leverage our technology and development capabilities to accelerate their discovery and development efforts.

Collaborations are welcome for the use of Precision.AI in:

  • Oncology
  • Immunology
  • Children Diseases
  • Neurological disorders

 

DrugTX.AI platform for drug development efforts in:

  • Clinical
  • Manufacturing
  • Commercial

Contact : sharmav@myraebsytems.com for partnering opportunities. 

Get in touch with us

Linkedin

Myra EB Systems

©2024. All Rights Reserved by Myra EB Systems